Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
VA West Los Angles Medical Center
mi
from
Los Angeles, CA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
VA West Los Angles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
UCLA
mi
from
Los Angeles, CA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
SouthCoast Imaging Center
mi
from
Savannah, GA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
SouthCoast Imaging Center
mi
from
Savannah, GA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Saint Lukes Hospital
mi
from
Kansas City, MO
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Saint Lukes Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
John Cochran Veterans Administration
mi
from
Saint Louis, MO
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
John Cochran Veterans Administration
mi
from
Saint Louis, MO
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Saint Louis University
mi
from
Saint Louis, MO
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
New York Presbyterian Weill Cornell
mi
from
New York, NY
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
New York Presbyterian Weill Cornell
mi
from
New York, NY
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
University of Utah School of Medicine
mi
from
Salt Lake, UT
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
University of Utah School of Medicine
mi
from
Salt Lake, UT
Click here to add this to my saved trials
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
A Phase 1b, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients
Status: Enrolling
Updated:  12/3/2012
UC Davis Health System Internal Medicine: Hematology & Oncology
mi
from
Sacramento, CA
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
A Phase 1b, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients
Status: Enrolling
Updated: 12/3/2012
UC Davis Health System Internal Medicine: Hematology & Oncology
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
A Phase 1b, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients
Status: Enrolling
Updated:  12/3/2012
RUSH Hemophilia & Thrombophilia Center
mi
from
Chicago, IL
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
A Phase 1b, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients
Status: Enrolling
Updated: 12/3/2012
RUSH Hemophilia & Thrombophilia Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
Status: Enrolling
Updated:  12/19/2012
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
Status: Enrolling
Updated: 12/19/2012
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
Click here to add this to my saved trials
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated:  12/19/2012
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated: 12/19/2012
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated:  12/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated: 12/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
Status: Enrolling
Updated:  12/19/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
Status: Enrolling
Updated: 12/19/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Randomized Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic GM-CSF-based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Status: Enrolling
Updated:  1/14/2013
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Randomized Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic GM-CSF-based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Status: Enrolling
Updated: 1/14/2013
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated:  1/17/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated: 1/17/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated:  1/17/2013
Pfizer Investigational Site
mi
from
Houston, TX
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated: 1/17/2013
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated:  1/17/2013
Pfizer Investigational Site
mi
from
Seattle, WA
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated: 1/17/2013
Pfizer Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Stanford Univ Med Ctr
mi
from
Stanford, CA
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Robert H. Lurie Comprehensive Cancer Center Northwestern University
mi
from
Chicago, IL
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Robert H. Lurie Comprehensive Cancer Center Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Johns Hopkins Kimmel Cancer Center
mi
from
Baltimore, MD
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Johns Hopkins Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Institute for Drug Development
mi
from
San Antonio, TX
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Institute for Drug Development
mi
from
San Antonio, TX
Click here to add this to my saved trials
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  1/23/2013
Mount Sinai School of Medicine
mi
from
New York, NY
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 1/23/2013
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  1/23/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 1/23/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  1/23/2013
New York University Cancer Institute
mi
from
New York, NY
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 1/23/2013
New York University Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  1/23/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 1/23/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status: Enrolling
Updated:  1/24/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status: Enrolling
Updated: 1/24/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status: Enrolling
Updated:  1/24/2013
Colorado Blood Cancer Institute
mi
from
Denver, CO
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status: Enrolling
Updated: 1/24/2013
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status: Enrolling
Updated:  1/24/2013
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status: Enrolling
Updated: 1/24/2013
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status: Enrolling
Updated:  1/24/2013
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Status: Enrolling
Updated: 1/24/2013
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  1/29/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 1/29/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  1/29/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 1/29/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  1/29/2013
Children's Hospital - Boston
mi
from
Boston, MA
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 1/29/2013
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  1/29/2013
Massachusetts General Hospital
mi
from
Boston, MA
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 1/29/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  1/29/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 1/29/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma
A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  1/31/2013
Hillman Cancer Center
mi
from
Pittsburgh, PA
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma
A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 1/31/2013
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study Investigating Treatment Factor X in People With Factor X Deficiency
A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.
Status: Enrolling
Updated:  2/4/2013
UCSF School of Medicine
mi
from
San Francisco, CA
A Study Investigating Treatment Factor X in People With Factor X Deficiency
A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.
Status: Enrolling
Updated: 2/4/2013
UCSF School of Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Investigating Treatment Factor X in People With Factor X Deficiency
A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.
Status: Enrolling
Updated:  2/4/2013
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
A Study Investigating Treatment Factor X in People With Factor X Deficiency
A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.
Status: Enrolling
Updated: 2/4/2013
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Investigating Treatment Factor X in People With Factor X Deficiency
A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.
Status: Enrolling
Updated:  2/4/2013
Dr. William Mitchell New York Blood Center, Weill Cornell Medical College
mi
from
New York, NY
A Study Investigating Treatment Factor X in People With Factor X Deficiency
A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.
Status: Enrolling
Updated: 2/4/2013
Dr. William Mitchell New York Blood Center, Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)
RDCRN 5110, Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)(Version 24Feb12, NIH Approved 4/5/2012)
Status: Enrolling
Updated:  2/4/2013
Baylor College of Medicine
mi
from
Houston, TX
Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)
RDCRN 5110, Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)(Version 24Feb12, NIH Approved 4/5/2012)
Status: Enrolling
Updated: 2/4/2013
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Changes in Bleeding and Clotting During the Menstrual Cycle
Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
Status: Enrolling
Updated:  2/6/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Changes in Bleeding and Clotting During the Menstrual Cycle
Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
Status: Enrolling
Updated: 2/6/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
University of Chicago Medical Center
mi
from
Chicago, IL
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials